

# Factor VIII Inhibitor Point of Care Test


**Domain:** Diagnostic Assay/Kit

**About Technology:** The technology uses gold nanoparticles conjugated with Factor VIII antigen for highly specific detection of FVIII inhibitors in plasma, enhancing antigen-antibody binding for improved assay performance. Internal validation demonstrated >90% sensitivity and specificity for detecting high-titer inhibitors (>5 BU), making it a reliable tool for monitoring hemophilia A patients at risk of clinically significant inhibitor development

**Intended Use:** Detect FVIII inhibitors in hemophilia A patients

**Advantages:**

- 20-min gold nanoparticle LFIA for rapid FVIII inhibitor detection with minimal equipment.
- Low cost (~₹100) and easy to use
- Compatible with Emicizumab and faster, more accessible, and more affordable than conventional assays.



**IP Status:** Filed (Indian Patent application No.- 202511083527)

**Development Status:** Internal validation completed

**Institute(s):** ICMR-National Institute of Immunohaematology (NIIH)

**Inventor(s):** Dr. Rucha Patil, Sharda Shanbhag, Sweta Kaskar, Moni Singh

For Licensing Opportunities contact: [patentmitra.hq@icmr.gov.in](mailto:patentmitra.hq@icmr.gov.in)